Zhi Tong Cai Jing·2025-09-02 11:42Core Viewpoint - Junshi Biosciences (688180.SH) announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of JT118 injection, aimed at preventing monkeypox virus infection [1] Group 1 - JT118 is a "dual-target" recombinant protein vaccine composed of monkeypox virus antigens A35 (extracellular membrane virus antigen) and M1 (intracellular mature virus antigen) [1] - The vaccine is primarily intended for the prevention of monkeypox virus infection, which is a zoonotic viral disease caused by the monkeypox virus [1] - The monkeypox virus is classified under the Poxviridae family and the Orthopoxvirus genus, producing two different infectious particle forms during replication: extracellular membrane virus and intracellular mature virus [1] Group 2 - JT118 retains the epitope structures of both natural antigens A35 and M1, while significantly increasing molecular weight through multi-antigen fusion, which is more conducive to immune activation [1]